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Background: Malaria is a deadly parasitic disease that affects more than 3 billion people worldwide, in predominantly
resource-poor countries. Despite malaria being preventable and treatable, a large number of adults and children,
mostly in Africa, die from this disease each year. One contributor to needless morbidity and mortality is the production
and distribution of poor-quality antimalarial medicines; indeed, it is estimated that over 122,000 deaths of children
under 5 years of age in sub-Saharan countries were caused by poor-quality antimalarial medicines, in 2013 alone.
Discussion: Poor-quality medicines include those that are deliberately falsified for monetary gain and may contain
incorrect amounts or even no active ingredients at all, as well as products that are inadequate due to poor compliance
to conventional quality standards and medicines that have degraded over time. Across a number of studies it has been
reported that 4-92% of antimalarials tested are poor quality. This represents a massive risk to the population subjected
to the use of these medicines, in the form of more severe and prolonged illness, additional costs to individuals who
already have very little money, and lack of confidence in treatments. The continuing circulation of poor-quality
medicines results from a number of factors, including insufficient regulatory capacity in susceptible countries,
inadequate funding to perform regulatory functions, poor coordination between regulatory authorities, and
inefficient import/export control systems.
To combat the distribution of poor-quality medicines a number of organisations have developed guidelines for the
procurement of antimalarials, and programs to educate consumers about the risks of poor-quality medicines and
incentivise retailers to identify and report falsified medicines. The development of new technologies to quickly identify
poor-quality medicines in the field is also essential, and some significant advances have been made.
Conclusion: There has been considerable improvement in the delivery of high-quality antimalarials to those who need
them; however, there is still an urgent need for a collective response by the international community, political leaders,
regulatory bodies, and pharmaceutical companies. This should include political commitment for enhanced research
and development funding, such as for new innovative track-and-trace field devices, and international efforts to
strengthen and harmonise drug regulation practices.
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Malaria, a deadly parasitic infection transmitted by mos-
quitoes, affects more than 3 billion people worldwide in
95 predominantly resource-poor countries [1]. In 2015,
despite a reduction in incidence, 212 million new cases
of malaria were reported, resulting in an estimated
429,000 deaths; the vast majority (approximately 90%) of
new cases and estimated deaths were in developing
countries in the World Health Organisation (WHO)
African Region [2]. Over 70% of the malaria deaths in
Africa (nearly 300,000 deaths) occurred in children
under 5 years of age [3]. Two countries, Nigeria and
Democratic Republic of the Congo, account for more
than 35% of the malaria cases worldwide and a similar
proportion of deaths from malaria [2]. In a 3-month
period in 2016, nearby Ghana had over 2.2 million sus-
pected malaria cases, resulting in nearly 80,000 hospital
admissions, almost 50% of which were for children
under 5 years of age [4].
Despite the high morbidity and mortality resulting
from malaria infection, this is a preventable, curable
disease. Vector control, using insecticide-treated mos-
quito nets and indoor residual spraying, is the main
approach to prevent and reduce malaria transmission,
while the use of high-quality antimalarial medicines has
the potential to save hundreds of thousands of lives each
year. Access to antimalarial drug therapy and the grow-
ing resistance of (i) malarial parasites to artemisinin and
(ii) mosquitoes to insecticides, are significant concerns
in malaria control and elimination.
An added challenge is the circulation of poor-quality
antimalarials (PQAs) in the markets of endemic coun-
tries. In a sample of 39 sub-Saharan countries, it was es-
timated that 122,350 deaths in children under 5 years of
age (representing 3.75% of all deaths for that age group)
were caused by PQAs in 2013 alone [5]. This represents
approximately 20% of all malaria deaths in children
under 5; these were unnecessary and avoidable deaths.
What are poor-quality medicines?
Poor-quality medicines (PQMs) can be classified as being
in one of three categories: falsified, substandard or de-
graded. Falsified medicines are “deliberately and fraudu-
lently mislabelled with respect to identity and/or source”,
primarily created for monetary gain at the expense of
patient health [6]. These medicines may contain the incor-
rect type or quantity of active pharmaceutical ingredients
[6]. Substandard medicines are produced by legitimate
manufacturers; however, the products are not compliant
with quality standards. The lack of quality control may be
deliberate or inadvertent. Substandard medicines contain
incorrect amounts of active pharmaceutical ingredients, or
may not be sufficiently bioavailable following administra-
tion. Degraded medicines begin as high-quality medicines,but either pass their expiry date or are exposed to adverse
environmental conditions during transport or storage, such
as extreme temperature, relative humidity or direct expos-
ure to sunlight. If environmental conditions are not prop-
erly controlled along the entire supply route, high-quality
medicines may become degraded and unwittingly, or con-
sciously, be distributed and used. Regardless of the cause,
the use of PQMs can have devastating impacts on patient
health, as well as potentially promote the development of
drug resistance [7], which can significantly impact entire
populations requiring these medicines.
How big is the problem?
Poor-quality antimalarials are a major impediment to
malaria control, especially in resource-poor societies. A
2012 review of data from 1999 to 2010 revealed that of
the samples tested, more than one-third of antimalarials
supplied and distributed in South-East Asia and sub-
Saharan Africa were of poor quality, with respect to fail-
ing chemical analyses or being classified as falsified [8].
Furthermore, a 2009 study found 26, 30 and 44% of
antimalarials from Uganda, Madagascar and Senegal,
respectively, failed quality control tests [9]. A review of
reports published from 2011 to 2017 reveals that be-
tween 4 and 92% of antimalarials examined were sub-
standard in some fashion (Table 1); the percentage of
antimalarials that were found to be poor quality is indi-
cative of the complex situation that exists, where the
presence of PQAs is dependent on a combination of
factors, including the cost and accessibility of high-
quality antimalarials, and the presence of adequate drug
control regulations in individual countries; it is clear that
some countries have extensive difficulties with PQAs
while other countries are impacted to a lesser degree.
These data indicate a significant proportion of antima-
larials being distributed in developing countries are
potentially of inadequate quality.
Impact of poor-quality antimalarials in “low” and
“middle” income countries
The use of PQAs can have multiple consequences, in-
cluding an increased risk of developing drug-resistant
strains of malaria, as the sub-therapeutic doses of medi-
cines will be ineffective in destroying all of the parasites
[10], reduced consumer confidence in a specific treat-
ment, and potentially prolonged and more severe illness
[5]. Loss of consumer confidence has damaging effects
on subsequent public health programs, even when they
seek to deliver high-quality, effective treatments [8].
There are also significant financial consequences for pa-
tients who purchase PQAs, as they are now out of
pocket for medicines that do not help, and are then
forced to pay for additional treatments. It is also possible
that patients may suffer unexpected adverse effects or
Table 1 A partial summary of PQAs reported in the literature from 2011 to 2017
Drug(s) Issue Number of PQM
failed/tested (%)
Country Study
Artemisinin-based
drugs, halofantrine
Incorrect amount of API,
API absent entirely,
quinine substituted for
artesunate
35/59 (59%) Burkina Faso, Chad, Cameroon,
Democratic Republic of the
Congo, Ghana, Kenya, Nigeria,
Rwanda, Senegal
Newton et al. 2011 [34]
Artesunate No artesunate present 1 (case report) Equatorial Guinea Chaccour et al. 2012 [13]
Artemisinin-based
drugs, chloroquine,
primaquine
Incorrect amount of API 18/77 (23%) Guyana Evans et al. 2012 [35]
Incorrect packaging 30/77 (38%)
Artesunate and
amodiaquine
Incorrect amount of API 13/16 (81%) Ghana Affum et al. 2013 [36]
Artemisinin-based
drugs
Incorrect amount of API 13/14 (92%) Ghana El-Duah et al. 2012 [37]
Artemisinin-based
drugs, chloroquine,
quinine, primaquine,
amodiaquine
Incorrect amount of API 36/301 (11%) Papua New Guinea Hetzel et al. 2014 [38]
Artemisinin-based
drugs
Incorrect amount of API 94/124 (by HPLC)
(75%) 112/125
(by SQ-TLC)
(89%)
Ghana and Togo Osei-Safo et al. 2014 [39]
Artemisinin-based
drugs
Incorrect amount of API 69/1737 (4%) Tanzania ACT Consortium Drug
Quality Project Team
2015 [40]
Artemisinin-based
drugs
Incorrect amount of API 206/3024 (6%) Nigeria Kaur et al. 2015 [41]
Falsified (0% API) 35/3024 (1%)
Degradation products of
API present
38/3024 (1%)
Artemisinin-based
drugs, chloroquine,
quinine, sulfadoxine/
pyrimethamine
Incorrect amount of API,
incorrect labelling
8/28 (28%) Cambodia Yong et al. 2015 [42]
Incorrect amount of API 1/7 (14%) Indonesia
Incorrect amount of API,
counterfeit packaging
15/30 (50%) Laos
Incorrect amount of API 1/10 (10%) Myanmar
Incorrect amount of API 4/8 (50%) Thailand
Incorrect amount of API 1/12 (8%) Vietnam
Artemisinin-based
drugs
Incorrect amount of API 91/291 (31%) Cambodia Yeung et al. 2015 [43]
Expired at time of purchase 21/212 (9%)
Range of antimalarial
drugs
Incorrect amount of API 9/146 (6%) Laos Tabernero et al. 2015 [44]
Range of antimalarial
drugs
Incorrect amount of API 12/37 (32%) Afghanistan Lalani et al. 2015 [45]
Artemisinin-based
drugs
Expired at time of purchase 23/256 (8%) Ghana Tivura et al. 2016 [46]
Incorrect amount of API 90/254 (35%)
Quinine sulfate Incorrect amount of API 7/56a (12%) Malawi Khuluza et al. 2017 [47]
Sulfadoxine/
pyrimethamine
(multiple different
samples)
Both stated APIs absent
but other APIs present;
falsified identity; incorrect
amount of API
Artemisinin-based
drugs
Incorrect amount of API 11/30 (36%) Nigeria Izevbekhai et al. 2017 [48]
API active pharmaceutical ingredient, HPLC high-performance liquid chromatography, SQ-TLC semi-quantitative thin-layer chromatography; a - pharmaceuticals
tested included antibiotics
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contaminants or degradation products [10, 11]. There
are reports of individuals who have died or had pro-
longed illnesses as a direct result of taking PQAs that
did not contain a therapeutic amount of the active in-
gredient [10, 12–14].Improved understanding of the problem, regulatory
control and monitoring
There are many factors that contribute to the circula-
tion of PQAs. Accurate reports of the extent of PQAs
in different regions are essential in targeting all aspects
of the problem, from drug production, to supply and
procurement. A study in 2014 found that 63 of 104
countries (60%) with endemic malaria had no published
reports of antimalarial quality [15], revealing critical
gaps in essential data and an inability to identify PQA
hotspots. Furthermore, there is no global system for
identifying and reporting PQAs, with those in a pos-
ition to respond to the presence of PQAs not being in-
formed quickly enough to act on the problem [16].
Many of the countries that are subject to high levels of
PQAs suffer serious gaps in their regulatory capacity, in-
cluding shortages of adequately trained staff, inadequate
funding to perform regulatory functions, poor coordin-
ation between regulatory authorities, medicine registration
guidelines and assessment methods that do not meet
WHO standards, and inefficient import/export control
systems [17, 18]. Together, these issues make it difficult to
identify and halt the movement and use of PQAs.
Lack of international supply chain regulation is another
significant issue. There are many vulnerable points, from
the purchase of individual drug components, production
of final formulations, and the export of drugs for pack-
aging and sale, that can be targeted or provide an oppor-
tunity for the introduction of falsified or substandard
medicines [18, 19]. Currently, there are no coordinated
international processes for monitoring all aspects of medi-
cine delivery, including monitoring transport and storage
conditions at all points in the supply chain to prevent deg-
radation of genuine antimalarial medicines.
Furthermore, if falsified/substandard medicines and
the individuals/companies who produced/supplied them
are identified, there is little that can be done legally to
stop this trade. International laws are not harmonised to
prosecute in this matter and penalties are insignificant
[20]. Proposals have been made to strengthen and
standardise international law with regards to falsified/
substandard medicines [20, 21] but any changes will
take time to implement and ideally require the back-
ing and advocacy of multiple stakeholders, including
governments, public health officials and the pharma-
ceutical industry.Preventing the distribution of PQAs
There have been significant efforts to stop the trafficking
of all PQMs, in operations led by INTERPOL and in-
volving local, national and international organisations
[11]. For example, Operation Pangea targets the sale of
illegal medicines online, including PQMs, and Operation
Mamba targets the trafficking of falsified medicines in
East Africa. Whilst these operations are invaluable and
have unquestionably removed falsified medicines from
the supply chain [11], their continuation is essential to
facilitate widespread access to high-quality medicines for
life-threatening but treatable diseases. Ideally, affordable
medicines will be readily available to treat malaria;
expensive medicines or those that experience high
demand/low supply provide the perfect setting for
selling PQAs to those who cannot afford genuine
medicines [19, 22].
Programs that target all aspects of PQAs, from supply
and distribution to procuring legitimate, high-quality
medicines, are necessary to stop the cycle of PQA deliv-
ery to patients at risk. For example, the US President’s
Malaria Initiative works with a variety of local and inter-
national partners to prevent the distribution of PQAs,
including: educating consumers about the risks of buy-
ing falsified and sub-standard medicines, incentivising
shopkeepers to report suspected falsified medicines, and
working with regulatory authorities to improve medicine
quality. The US Pharmacopeial (USP) Convention has
the Regulatory Standards Assistance Program, which
“provides developing countries with tools to increase
their capacity to test the quality of medicines for their
citizens”, including reference standards “to strengthen
the reliability of quality control tests” [23].
Medicine procurement and supply chains can be infil-
trated with falsified medicines, so a number of non-
Government organisations have guidelines regarding the
procurement of malaria medicines to strengthen supply
chains and ensure falsified medicines are not distributed to
patients. To support the procurement of high-quality med-
icines, the WHO, along with global partners, developed
and manage the Prequalification of Medicines Programme
(PQP), aimed at assessing the quality, safety and efficacy of
medicines produced by specific manufacturers [24]. This
informs government and non-government organisations
of manufacturers that are complying with WHO stan-
dards for medicine production, and performs ongoing
inspections and monitoring to ensure medicines remain
of high quality [23, 24].
Need for additional resources
There are currently no standardised guidelines regarding
the methods used and subsequent reporting measures
for medicine quality; calls for a standardised set of
guidelines for detecting and reporting medicine quality
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published a series of guidelines for the conduct of such
field surveys [27].
The ability to quickly detect falsified or substandard an-
timalarials in the field is essential in preventing the trade
in poor-quality treatments [28]. A variety of qualitative
and semi-quantitative tests are currently used to assess
whether an antimalarial drug is falsified or substandard
[25]. The gold standard for testing chemical content is
methods such as high-performance liquid chromatog-
raphy (HPLC) or mass spectrometry (MS), which require
expensive equipment, trained personnel and specialist
maintenance, and are not necessarily available to the
countries most affected by PQAs [25]. Thus, there has
been an investment in developing new methods to quickly
and accurately test the quality of medicines in the field.
The US Food and Drug Administration developed the
counterfeit detection device version 3 (CD-3), which uses
light-emitting diodes (LEDs) to detect changes in the
reflected light that indicate a product may be falsified; this
method is very accurate and does not destroy the tablet
blister pack [29]. The counterfeit drug indicator (CoDI)
uses a laser and photoresistor to detect light intensity
emitted through a tablet as a result of tablet thickness,
density and the wavelength of light emitted by the tablet;
this provides a unique light intensity value, which can be
compared to genuine tablets [30]. These methods require
relatively inexpensive equipment and are simple to use,
making them ideal for field surveys and ongoing monitor-
ing at the point of care in developing countries.
Multidimensional conceptual frameworks for action
have previously been described by Pribluda et al. [31] as
well as the WHO [32, 33], and a commitment to follow
these frameworks will aid in the delivery of high quality
antimalarials to where they are needed.Conclusion
There have been considerable efforts to improve the deliv-
ery of high-quality antimalarials to those who need them.
However, there is still an urgent need for a collective
response by the international community, political leaders,
regulatory bodies, and pharmaceutical companies. This
should include political commitment for enhanced re-
search and development funding, such as for new innova-
tive track-and-trace field devices, and international efforts
to strengthen and harmonise drug regulation practices.
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